Authors
Latest:
How Genomic Sequencing Can Aid in Diagnosing Fungal InfectionsShaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) talks about how his team developed a test to identify fungi, and how they utilize it to diagnose, make treatment adjustments, and rule out hospital acquired infections.
Latest:
Potential Game Changer: Using AI for Antibiotic DevelopmentCésar de la Fuente, PhD, provides insights on the promising work of his lab as they accelerate the speed of finding new antimicrobial molecules.
Latest:
Mixed Fungal Brain AbscessClinicians review a patient case including diagnosis, treatment, and follow-up.
Latest:
NAFLD Is Increasingly Affecting Patients With HIVThe prevalence of this disease in this patient population is much higher than in the general public.
Latest:
SPREADing the Love: The Importance of Mentorship in PharmacyIn the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.
Latest:
ViiV Healthcare Presents Potential Long-Acting HIV TherapiesPhase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.
Latest:
The Role of Pharmacists in the World of Pediatric Antimicrobial StewardshipThe limitation in the number of pediatric-specific guidelines by professional organizations, and results from large randomized clinical trials, may place an additional emphasis on literature evaluation skills for pediatric ASP pharmacists.
Latest:
Advice for Physicians to Manage C. Difficile Infection (CDI)Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
Latest:
A Passion for Infectious Disease Education and CommunicationIn our latest podcast, Tim Gauthier, PharmD, BCPS, BCIDP, discusses all things pathogens and antibiotics. He also details the opportunities presented for antimicrobial stewardship when it combines diagnostics and treatment duration.
Latest:
Barriers That Reduce Pneumococcal Vaccine Uptake Among SeniorsThe most common reasons include finances, logistics, availability of information, and hesitancy or refusal.
Latest:
The Consequences of Doxycycline Postexposure ProphylaxisDoxycycline postexposure prophylaxis is associated with emerging tetracycline resistance in Neisseria gonorrhoeae and commensal organisms, highlighting the need for cautious, targeted use.
Latest:
What We Know But Still Have to Learn About Long COVIDDespite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
Latest:
Exploring the Recently Approved and Upcoming Clostridioides difficile TherapeuticsThis market has seen a flurry of activity, as shown by a review of the latest agents.
Latest:
An Education Opportunity for Transplant and Oncology InfectionsJohns Hopkins is offering its Pamela Tucker transplant and oncology infectious diseases course. Its director, Shmuel Shoham, MD, offers more information about this continuing education opportunity.
Latest:
INSTIs and Cardiovascular Outcomes: More ComplexityThe significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Latest:
Treating Persistent Methicillin-susceptible Staphylococcus aureus (MSSA) BacteremiaEmerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).
Latest:
A Review of the Currently Available Monoclonal Antibodies for COVID-19Outside of vaccines, these underutilized therapies are the best defense against severe disease.
Latest:
European Commission Approves Merck's Capvaxive for Adult Pneumococcal Disease PreventionNew 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.
Latest:
Vancomycin AUC Implementation in Resource-Limited Settings and its Associated DifficultiesThe latest article from SIDP illustrates the challenges of area under the curve (AUC) implementation and offers insights for strategies and resources to overcome them.
Latest:
Gilead's Once Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 StudyNew pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention
Latest:
Immunocompromised Patients on OPAT Face Nearly Double the Risk of 30-Day ReadmissionChristina Lee, PharmD, and Julia Donahue, PharmD, analyzed 533 encounters revealing a 27.1% readmission rate in immunocompromised patients versus 14.1% in non-immunocompromised patients.
Latest:
Now is Not the Time for Funding Pauses, Cutting Ties With Health OrganizationsBiocontainment, including the most recent threat of highly pathogenic avian influenza, demands we continue to finance research, and continue cooperation with important organizations like the WHO.
Latest:
When Should We De-Escalate Empiric Antimicrobials?De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
Latest:
Opposing Forces During COVID-19: Perspective From the ICUConflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Latest:
Community-Acquired Candida Glabrata Empyema: An Atypical Diagnosis Not to MissAlthough this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
Latest:
GigaGen Doses First Patient in Phase 1 Trial of GIGA-2339, a Potential Functional Cure for Chronic Hepatitis BCombining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.
Latest:
COVID-19 Booster Shots and the FutureKey opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Latest:
Oral Carbapenems: Promise, Peril, and PushbacksHere is a review of the literature for this class of antibiotics.
Latest:
Moving Beyond One-Size-Fits-All: The Future of Microbiome Therapy for C diff and BeyondIn Part 2, Anna Seekatz, PhD and PhD candidate Sophie Millard highlight the need for precision microbial therapies tailored to host-specific gut environments.
